| Subcategory |
Measure |
01 IAGI/IGA |
02 TSS |
03 PASI |
04 PAGI/PGA |
05 Combined end point |
| 01 Calcipotriol vs. dithranol |
Effect size [CI] |
(SMD ‐0.43; 95% CI ‐0.85 to ‐0.01) |
(SMD ‐0.54; 95% CI ‐1.16 to 0.08) |
(SMD 0.73; 95% CI ‐0.55 to 2.00) |
(SMD ‐0.05; 95% CI ‐0.90 to 0.80) |
(SMD 0.07; 95% CI ‐0.57 to 0.71) |
| 02 Calcitriol vs. dithranol |
Effect size [CI] |
(SMD 0.51; 95% CI 0.13 to 0.88) |
(SMD 0.13; 95% CI ‐0.24 to 0.50) |
(SMD ‐0.21; 95% CI ‐0.58 to 0.16) |
‐ |
(SMD 0.51; 95% CI 0.13 to 0.88) |
| 03 Tacalcitol vs. dithranol |
Effect size [CI] |
‐ |
(SMD ‐0.18; 95% CI ‐0.60 to 0.25) |
(SMD ‐0.07; 95% CI ‐0.50 to 0.36) |
‐ |
(SMD ‐0.18; 95% CI ‐0.60 to 0.25) |
| All treatments |
Effect size [CI], I² statistic |
(SMD ‐0.24; 95% CI ‐0.72 to 0.25); I² statistic:93.0% |
(SMD ‐0.27; 95% CI ‐0.73 to 0.20); I² statistic: 80.6% |
(SMD 0.36; 95% CI ‐0.33 to 1.04); I² statistic: 94.5% |
(SMD ‐0.05; 95% CI ‐0.90 to 0.80); I² statistic: 92.5% |
(SMD 0.09; 95% CI ‐0.44 to 0.63); I² statistic: 94.9% |
| ‐ |
No. participants |
1108 |
386 |
796 |
544 |
1284 |
| ‐ |
Between‐patient design |
5 |
3 |
5 |
2 |
7 |
| ‐ |
Within‐patient design |
0 |
1 |
0 |
0 |
1 |
| ‐ |
Treatment duration |
8 wks to 12 wks |
4 wks to 8 wks |
8 wks to 12 wks |
8 wks to 12 wks |
4 wks to 12 wks |
